Drug Trial Radar · NCT02797821
Pharmacokinetic and Dose Response Study of Asfotase Alfa in Adult Patients With Pediatric-Onset Hypophosphatasia (HPP)
Last checked: Nov 20, 2026Latest source record: Sep 17, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
27
Actual
Start
Jun 6, 2016
Primary completion
Jun 21, 2017
Study completion Jun 21, 2017
Sponsor
- Lead sponsor
- Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jun 14, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of asfotase alfa in adult participants with pediatric-onset HPP.
Conditions
- Hypophosphatasia
Interventions
Asfotase alfaDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change In Plasma PPi From Baseline To Pre-3rd Dose At Week 9Time frame: Baseline to Week 9
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
Shriners Hospitals for Children
St Louis, Missouri
Duke University Medical Center
Durham, North Carolina
Vanderbilt Medical Center Endocrinology
Nashville, Tennessee
University of Würzburg
Würzburg, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.